Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sunlenca
Pharma
Gilead's PrEP shows early promise in once-yearly dosing
Once-yearly lenacapavir achieved blood concentrations that exceeded those associated with the strong efficacy that its twice-yearly version showed.
Angus Liu
Mar 11, 2025 2:30pm
Gilead charts course for long-acting PrEP launch
Feb 12, 2025 9:12am
GSK questions Gilead's potential dominance of the PrEP market
Feb 6, 2025 2:20pm
Gilead spotlights lenacapivir in plan to hold on to HIV crown
Dec 11, 2024 10:53am
GSK bolsters case for long-acting HIV PrEP drug Apretude
Oct 16, 2024 1:26pm
Gilead inks licensing deals to boost lenacapivir access
Oct 2, 2024 3:14pm
